Guard Therapeutics International AB (publ), formerly A1M Pharma AB, is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-17	SEK 1.650	+3.12%	4,656
26-07-16	SEK 1.600	+3.23%	22,730
26-07-15	SEK 1.550	+0.13%	10,292
26-07-14	SEK 1.548	-1.90%	2,933
26-07-13	SEK 1.578	+1.15%	19,418

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-07-17 EDT			5-day change	1st Jan Change
1.650 ^SEK	+3.12%		+5.77%	+12.24%

07-17	Guard Therapeutics Gets Conditional Approval For Continued Listing	RE
07-17	Guard Therapeutics Secures Conditional Nasdaq Listing Approval Ahead of Disruptive Pharma Takeover	MT

Market Cap	33.28M 3.45M 3.02M 2.78M 2.56M 4.84M 332M 4.94M 13.07M 163M 12.96M 12.67M 565M	P/E 2024	-2.24x	P/E 2025	-0.24x
Enterprise Value	-16.55M -1.72M -1.5M -1.38M -1.28M -2.41M -165M -2.46M -6.5M -80.91M -6.44M -6.3M -281M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	65.85%	Yield 2024 *	-	Yield 2025	-

07-17	Guard Therapeutics Gets Conditional Approval For Continued Listing	RE
07-17	Guard Therapeutics Secures Conditional Nasdaq Listing Approval Ahead of Disruptive Pharma Takeover	MT
06-12	Guard Therapeutics Initiates Divestment of GTX Platform	MT
06-11	Guard Therapeutics to Acquire Disruptive Pharma in Reverse Takeover	MT
06-11	Guard Therapeutics announces reverse takeover and planned name change	FW
06-09	Disruptive Pharma Holding Ab entered into a conditional agreement to acquire Guard Therapeutics International AB (OM:GUARD) in a reverse merger transaction in a transaction valued at SEK 61 million.	CI
05-11	Guard Therapeutics loss before and after tax SEK 6.4 mln	RE
05-11	Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-13	Seven stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
04-10	Three stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
03-31	Guard Therapeutics updates on strategic review	RE
03-31	Guard Therapeutics nears next phase of strategic review	FW
03-30	Guard Therapeutics International AB Provides Update on Strategic Review and Considers Multiple Strategic Alternatives	CI

25-10-26	Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study	CI
25-09-11	Redeye Initiates Coverage of Guard Therapeutics with Target Value of SEK 43	FW

Guard Therapeutics International AB Stock

Stocks

GUARD

SE0021181559

Biotechnology & Medical Research

Valuation: Guard Therapeutics International AB

Chart: Guard Therapeutics International AB

Latest news : Guard Therapeutics International AB

Last Transcript: Guard Therapeutics International AB

Analysts' recommendations: Guard Therapeutics International AB

Press Releases: Guard Therapeutics International AB

News in other languages: Guard Therapeutics International AB

Quotes and Performance

Course Extremes

Managers and Directors: Guard Therapeutics International AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

07-16	Guard Therapeutics Receives Conditional Approval for Continued Listing on Nasdaq First North Growth Market and Publishes Company Description	AQ
06-12	Guard Therapeutics Initiates Transaction Process for the GTX Platform	AQ
06-10	Guard Therapeutics has entered into a conditional agreement for a reverse takeover with Disruptive Pharma	AQ
04-09	Guard Therapeutics provides information regarding observation status on Nasdaq First North Growth Market	AQ
03-31	Guard Therapeutics provides update on strategic review	AQ

21-04-07	ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG
21-04-07	ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Zahlungsberichten gemäß § 116 WpHG

1 day	+3.13%
1 week	+5.77%
Current month	+3.12%
1 month	+8.55%
3 months	+31.79%
6 months	-29.79%
Current year	+12.24%

1 week	1.45	1.79
1 month	1.4	1.8
Current year	0.88	2.35
1 year	0.88	27
3 years	0.88	49.8
5 years	0.88	112.5
10 years	0.88	3,050

Manager	Title	Age	Since
Tobias Larsson Agervald CEO	Chief Executive Officer	50	2019-01-14
Karin Botha DFI	Director of Finance/CFO	53	2020-09-13
Michael Reusch CTO	Chief Tech/Sci/R&D Officer	66	2021-12-31

Director	Title	Age	Since
Göran Forsberg BRD	Director/Board Member	63	2019-05-28
Johannes Hulthe BRD	Director/Board Member	56	2019-05-28
Johan Bygge CHM	Chairman	70	2021-04-30

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/28/23	Peter Gilmour	Free		1,344,000	0.2672%
2/28/23	Tobias Larsson Agervald	Free	Chief Executive Officer	9,450,000	1.8784%
2/28/23	Camilla Svanstrom	Free		756,000	0.1503%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUARD THERAPEUTICS INTERNATIONAL AB	+3.12%	+5.77%	-91.87%	-77.24%	3.45M
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+376.72%	+599.59%	39.58B
BEONE MEDICINES AG	-1.70%	+4.46%	+7.46%	+57.67%	34.69B
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+26.35%	-6.83%	34.42B
CELLTRION, INC.	+0.06%	+0.34%	+2.32%	+29.30%	27.11B
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	16.21B
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+68.48%	+117.39%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+15.90%	+19.65%	14.05B
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+15.74%	-30.62%	13.02B
ABIVAX	-0.08%	-3.01%	+1,271.69%	+649.69%	11.76B
Average	+0.48%	+0.61%	+188.09%	+150.95%	20.62B
Weighted average by Cap.	+0.24%	+0.36%	+171.43%	+187.41%

	2024	2025
Net sales	-	-
Net income	-96.07M -9.96M -8.71M -8.04M -7.4M -13.97M -959M -14.27M -37.74M -470M -37.4M -36.58M -1.63B	-109M -11.29M -9.86M -9.11M -8.39M -15.83M -1.09B -16.17M -42.76M -532M -42.38M -41.45M -1.85B
Net Debt	-54.19M -5.62M -4.91M -4.53M -4.18M -7.88M -541M -8.05M -21.29M -265M -21.1M -20.63M -920M	-49.83M -5.17M -4.52M -4.17M -3.84M -7.25M -497M -7.4M -19.57M -244M -19.4M -18.97M -846M